The 5% Line David Einhorn Just Crossed, and the 9% Yield Paying for Solvay's Sputter

On the last day of August 2026, David Einhorn stopped being a 5% owner of Solvay. His Greenlight-affiliated funds, DME Advisors and DME Capital Management, filed the paperwork that every holder above that line eventually dreads or courts: a Belgian transparency notice recording that they dipped to 4.96% of the voting rights, a crossing "downwards," dated September 4, 2026. The reason listed in the disclosure was a disposal of voting securities. Translation: the most visible public bull of Solvay as a "boring essential chemicals" cash machine has begun to sell it.

Einhorn is not a peripheral name for Solvay holders. He is the thesis's author. In February 2024 he crossed the 3% line, and within weeks pushed through 5%. In April of that year he stood on stage at the Sohn Investment Conference and pitched the 160-year-old chemicals group as a top idea, calling it a "boring essential chemicals" business — the kind of predictable, cash-printing, share-buybacking company an old-school value investor was supposed to love. Soda ash, the commodity that has always set Solvay's tone, made up around 40% of sales. It looked like conviction with a microphone.

The word "boring" was always the tell. Soda ash may lack the drama of a technology stock, but it is still a cyclical commodity: prices rise, supply builds, prices fall, and the harvest goes to whoever bought cheap at the bottom of the cycle. Buying it when the bottom looked near, then watching the bottom move lower, is not a betrayal of the thesis; it is the thesis's normal weather. What the market did not sign up for was weather this bad.

The cash machine ran dry

By 2026, "boring" had come to mean something closer to "eroding." Solvay's second-quarter results, released July 29, showed underlying net sales down 7.4% organically and underlying EBITDA down 19.5% organically to €187 million, on continued weakness in soda ash pricing, particularly in the seaborne market. The Middle East conflict compounded it: the group's peroxides plant at Jubail, Saudi Arabia, has sat halted since mid-March, a roughly €20 million drag on quarterly earnings.

The consequence that matters most to anyone eyeing the dividend sits one level down. Solvay's free cash flow from continuing operations was €15 million in the first half of 2026, against €97 million a year earlier — and the second quarter was negative. Net debt rose to €1.8 billion and the leverage ratio climbed to 2.3x from 1.9x, with the company itself citing €254 million of dividend payments in the first half as a reason the debt went up. Management reaffirmed full-year guidance of underlying EBITDA between €770 million and €850 million and at least €200 million of free cash flow, but the cash testimony already delivered says the machine is not printing what it used to.

The yield is the trap

Here is where the two claims on the same pot of money collide. Solvay's stock yields roughly 9.4% on a forward dividend of €2.43 — a figure that screams "cheap" to an income investor and "at risk" to anyone doing the arithmetic. The business paid out €254 million in dividends in the first half of 2026 while generating €15 million of free cash flow. That gap did not vanish; it moved onto the balance sheet, which is exactly why leverage went up. The apparent gift was funded by the company's own credit line, and the hidden payer is whoever holds the stock when the bill comes due.

That is the uncomfortable fact the disclosure quietly raises: when the highest-profile advocate of the income story steps below a legally enforced disclosure line at the same moment the cash generation behind the yield is shrinking, the yield deserves to be read as a risk warning rather than an income gift. Careful, then, about what the filing does and does not prove. It confirms a sale and leaves DME still holding 4.96% — a large, continuing position, not an exit. It does not quantify the total he sold, because a fund need only announce that it crossed a threshold, not every share it trimmed. And the same denominator, 105,876,416, means this was a genuine disposal rather than dilution — DME did the selling.

Einhorn's disappearance is gradual because it is professional. Greenlight's own numbers show why a portfolio manager who trailed the market badly enough might trim a position that disappointed: the fund lost 4.3% in the second quarter and was up only 1.9% year to date against a market that gained 10.2%. By May 2026, when he pitched five turnaround stocks at Sohn, Solvay was not among them. The "boring essential chemicals" story has quietly been dropped from the public pitch deck.

None of this means Solvay is perishing. The rare-earth expansion at La Rochelle offers a real, if small, growth option, and management still expects positive full-year free cash flow. But the article of faith that made the stock exciting — that a famous value investor had found a cheap, predictable, high-yield compounder — has been revised by the man who wrote it. When the author of the thesis sells below the line that forces him to tell you, the retail investor holding a 9% yield is left with a two-sided choice: trust the company's stated full-year cash number over a first half that printed €15 million, or price in the possibility that the yield was never income at all, only deferred leverage. Einhorn chose a side in August. The filing is how the rest of us learned which one.